# Aurinia Pharmaceuticals Inc. (AUPH)

> Source: Nexqual · https://nexqual.com/AUPH · data as of 2026-10-28 20:00 UTC · cite as "Nexqual, Aurinia Pharmaceuticals Inc. (AUPH), nexqual.com/AUPH" · informational, not investment advice.

**Price:** USD 17.36 (+0.64% on the day) · last close of Oct 28, 2026; US market pre market, not a live price. Prev close 17.25 · day 17.05–17.38 · 52w 11.96–19.25 · market cap $2.31B · NGM

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $312M, net income $314M (100.8% margin) (SEC filings).
- Valuation: P/E 7.4x (avg 117.9x at the last 2 fiscal year-ends).
- Insider open-market sales, last ~7 months: 2 Form 4 filings, $546K; 2 not under a Rule 10b5-1 plan ($546K); 0 by opportunistic insiders, 2 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $12.5M; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 2.29 on a 1–5 scale) (7 analysts), mean target USD 18 (range 16–21).
- Total return with dividends: 1Y +42.1% vs S&P 500 +13.6%; 5Y -47.5% vs S&P 500 +79.8%.
- Next earnings: 2026-11-09, EPS estimate USD 0.22, revenue estimate $83.6M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $45.6M | $134M | $176M | $235M | $283M | $312M |
| Gross profit | $44.5M | $128M | $161M | $207M | $250M | — |
| Operating income | -$181M | -$111M | -$91.7M | -$4.7M | $105M | $151M |
| Net income | -$181M | -$108M | -$78.0M | $5.8M | $287M | $314M |
| EPS (diluted) | -$1.40 | -$0.76 | -$0.54 | $0.04 | $2.07 | — |
| Gross margin | 97.6% | 95.8% | 91.9% | 88.0% | 88.5% | — |
| Operating margin | -396.3% | -83.2% | -52.2% | -2.0% | 37.1% | 48.4% |
| Net margin | -396.8% | -80.7% | -44.5% | 2.4% | 101.5% | 100.8% |
| Revenue growth | -9.0% | +193.9% | +31.0% | +34.0% | +20.4% | — |
| Cash + short-term investments | $466M | $389M | $350M | $358M | $398M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 7.4x · P/S 7.4x · P/B 3.8x · Earnings yield 13.60% · Buyback yield (TTM) 3.62%
P/E at fiscal year-ends: Dec 2025 7.7x, Dec 2024 228.2x.

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 2 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-10 | Robertson Stephen P. | Chief Legal Officer | 11,939 | $190K | 2% | No | Routine (sold in Mar each year 2023–2025; this trade is outside those months) |
| 2026-08-21 | Robertson Stephen P. | Chief Legal Officer | 20,975 | $356K | 3.4% | No | Routine (sold in Mar each year 2023–2025; this trade is outside those months) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Insider purchases (SEC Form 4, open-market, last ~7 months)
1 purchase, $12.5M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-05-29…2026-06-02 | Tang Kevin | Chief Executive Officer | 814,606 | $12.5M | 15.29 | Too little history (no open-market trades in 2023) |

## Analysts
Consensus Buy (mean 2.29 on a 1–5 scale), 7 analysts; mean target USD 18 (low 16, high 21).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | TD Cowen | Target raised | Buy | $17 → $18 |
| 2026-08-07 | RBC Capital | Target raised | Sector Perform | $15 → $16 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-29) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +42.1% | -47.5% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +42.2% | -12.1% |
| Volatility (annualized) | 37.2% | 62.4% |
| Max drawdown | -21.8% (Jun 2026→Aug 2026) | -86.9% (Oct 2021→Dec 2022) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 91.97 -0.23% · ORKA (Oruka Therapeutics, Inc.) USD 95.97 +0.17% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.81 +1.58% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.9 +2.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.51 +0.92% · ABVX (Abivax SA) USD 89.84 +3.26%

## More
Full page: https://nexqual.com/AUPH · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Company outlook (8-K filed 2026-08-06)

- "Aurinia reiterates its guidance for 2026 total revenue of $315 million to $325 million, up 11% to 15% compared to 2025, and 2026 net product sales of $305 million to $315 million, up 12% to 16% compared to 2025."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.22 | $0.24 | -7.6% | $83.6M | 5 |
| Next quarter (ends 2026-12-31) | $0.21 | $0.23 | -8.8% | $85.7M | 5 |
| Current fiscal year (ends 2026-12-31) | $0.95 | $0.95 | -0.2% | $330.3M | 5 |
| Next fiscal year (ends 2027-12-31) | $1.17 | $1.11 | +5.5% | $388.4M | 5 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-09): ±9.5%; last 8 reports averaged ±6.3%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 22 | 42.0% | ±9.5% |
| 2026-12-18 | 50 | 40.1% | ±12.1% |
| 2027-01-15 | 78 | 44.5% | ±23.2% |
| 2027-04-16 | 169 | 43.5% | ±23.6% |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 6, 2026 | Quarter ended Jun 30, 2026 | $0.28 | $0.24 | Beat +16.7% | +4.3% |
| May 7, 2026 | Quarter ended Mar 31, 2026 | $0.25 | $0.20 | Beat +25.0% | -6.2% |
| Feb 26, 2026 | Quarter ended Dec 31, 2025 | $1.53 | $0.22 | Beat +595.5% | -1.8% |
| Nov 4, 2025 | Quarter ended Sep 30, 2025 | $0.23 | $0.16 | Beat +43.8% | +9.7% |
| Jul 31, 2025 | — | — | — | — | +15.9% |
| May 12, 2025 | — | — | — | — | -2.2% |
| Feb 27, 2025 | — | — | — | — | +0.0% |
| Nov 7, 2024 | — | — | — | — | +10.6% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-08-26 | Schedule 13D/A | ILJIN SNT Co., Ltd., ILJIN Steel Co., Ltd.: 4.4% of shares, 5%+ holder that may seek to influence the company (amended) | https://www.sec.gov/Archives/edgar/data/1600620/000110465926101785/0001104659-26-101785-index.htm |
| 2026-08-19 | 8-K | Other material event — “On August 19, 2026, Aurinia Pharmaceuticals Inc. (Aurinia or the Company) issued a press release announcing that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, "Aurinia") have entered into a settlement agreement with Teva Pharmaceuticals Inc. ("Teva") to resolve patent infringement litigation relating to Teva's filing of an Abbreviated New Drug Application seeking to market its generic 7.9 mg voclosporin oral capsules in the United States. A copy of the press release is attached hereto as Exhibit…” | https://www.sec.gov/Archives/edgar/data/1600620/000160062026000066/0001600620-26-000066-index.htm |
| 2026-08-06 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1600620/000160062026000062/0001600620-26-000062-index.htm |
| 2026-08-06 | 8-K | Quarterly results | https://www.sec.gov/Archives/edgar/data/1600620/000160062026000059/0001600620-26-000059-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.